pharma · Age-related Macular Degeneration · Neovascular Age-related Macular Degeneration · OTLK
Outlook Therapeutics NL
Outlook Therapeutics NL B. V.
Outlook Therapeutics is a pharma organization headquartered in Cranbury, USA. It trades on NYSE under ticker OTLK. Primary therapeutic focus areas include Age-related Macular Degeneration, Neovascular Age-related Macular
Cranbury, USA HQ
2011 Founded
59 Employees
Public company Type
OTLK · NYSE Ticker
Company details
- Status
- Public
- HQ
- Cranbury, USA
- Founded
- 2011
- Employees
- 59
- Programs
- 2
- Drugs
- 3
- Patents
- 2
bevacizumab
Phase 3 · mab · Age-related Macular Degeneration
bevacizumab for Age-related Macular Degeneration is a Phase 3 program (mab) at Outlook Therapeutics NL B. V. with 4 ClinicalTrials.gov record(s).
Internal code ONS-5010-001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Outlook Therapeutics NL B. V.
- Phase
- Phase 3
- Modality
- mab
- Indication
- Age-related Macular Degeneration
- Status
- active
- Trials
- 4